



IFW

PATENT

Attorney Docket No.: 18184-0001 CII

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Patent application of :  
Herbert W. Harris et al. :  
Serial No.: 10/728,286 : Group Art Unit:  
1614 :  
Filed: December 3, 2003 : Examiner:  
Kevin Weddington :  
For: METHOD OF INCREASING NEUTROPHIL :  
PRODUCTION USING 2,3- :  
BENZODIAZEPINES :

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, submitted herewith are copies of the references listed in the accompanying Form PTO-1449, except for any US patents and published US patent applications which may be listed.

The Examiner is respectfully requested to review the items listed on the attached form and make them of record in the instant application has required by M.P.E.P. §609. It is requested that the Examiner initial the enclosed duplicate Form 1449, and return one copy to the undersigned.

<p style="text-align: center;"><b>CERTIFICATE OF MAILING</b> <b>UNDER 37 C.F.R. 1.8(a)</b></p> <p>I hereby certify that this paper, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date indicated below, with sufficient postage, as first class mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.</p> <p>BY <u><i>[Signature]</i></u></p> <p>DATE: <u>9/27/06</u></p>
---

This Statement should not be construed as a representation that the cited references are material or prior art, or that more relevant references do not exist.

This Statement is being submitted before receipt of any office action on the merits. Thus, no fee is due for the filing of this paper. However, if a fee is due, please charge deposit account 50-0573.

Respectfully submitted,

HERBERT W. HARRIS et al.

BY 

DANIEL A. MONACO  
Registration No. 30,480  
DRINKER BIDDLE & REATH LLP  
One Logan Square  
18<sup>th</sup> and Cherry Streets  
Philadelphia, PA 19103-6996  
(215) 988-3312 - Phone  
(215) 988-2757 - Fax  
*Attorney for Applicants*

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.  
18184-0001CI1

SERIAL NO.  
10/728,286

**INFORMATION DISCLOSURE STATEMENT**

APPLICANT:  
Herbert W. Harris, *et al.*

FILING DATE  
December 3, 2003

GROUP  
1614

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	AA	6,864,251	03/08/2005	Kucharik, <i>et al.</i>	514	221	
	AB	2004/0138209	07/15/2004	Kucharik, <i>et al.</i>	514	221	
	AC	2004/0152695	08/05/2004	Harris, <i>et al.</i>	514	221	
	AD	2004/0157833	08/12/2004	Harris, <i>et al.</i>	514	221	

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AE	178519	09/28/1981		C 07 D	243/00	x	

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

AF	F. Galdiero, <i>et al.</i> , "Effects of Benzodiazepines on Immunodeficiency and Resistance in Mice", <i>Life Sci.</i> , 1995, 57(26), 2413-23.
AG	S. Kalashnikov, <i>et al.</i> , "Immunomodulating effects of tofizopam (Grandaxin®) and diazepam <i>in vitro</i> ", <i>Mediators of Inflammation</i> , 2002, 11, 53-59.
AH	K. Yoshikawa, <i>et al.</i> , "Clinical Evaluation of Grandaxin® (Tofisopam) on Several Skin Diseases", <i>Hifu</i> , 2003, 35(1): 195-202. (Translation provided).

**EXAMINER**

**DATE CONSIDERED**

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.